Loading...
•
Jun 30, 2022
ResMed Q4 2022 Earnings Report
ResMed's Q4 2022 results were announced, demonstrating revenue growth and market leadership.
Key Takeaways
ResMed Inc. reported a 4% increase in revenue, reaching $914.7 million, and a 6% rise in operating profit for the fourth quarter of fiscal year 2022. The company's diluted earnings per share stood at $1.33, while non-GAAP diluted earnings per share reached $1.49.
Revenue increased by 4% to $914.7 million, up 8% on a constant currency basis.
Gross margin grew 110 bps to 57.1%; non-GAAP gross margin grew 50 bps to 57.8%.
Income from operations increased 6%; non-GAAP operating profit up 4%.
Diluted earnings per share of $1.33; non-GAAP diluted earnings per share of $1.49.
ResMed
ResMed
ResMed Revenue by Segment
Revenue by Segment
Total Devices Revenue
CapyFin.comTotal Masks and other Revenue
CapyFin.com Forward Guidance
ResMed is confident in their ability to grow steadily throughout fiscal year 2023 and to continue delivering for all stakeholders. They are investing in R&D to drive accelerated adoption of digital health solutions in sleep apnea, COPD, and outside-hospital care, as they progress towards their goal to improve 250 million lives in 2025.
Revenue & Expenses
Visualization of income flow from segment revenue to net income